Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could flickering lights and tones help fight Alzheimer's? major trial underway

NCT ID NCT05637801

Disease control Sponsor: Cognito Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) version. The goal is to see if this sensory stimulation can preserve memory and daily living skills better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spectris™ AD device (sensory stimulation via light and sound)
What this could lead to
If it works, this could offer a non-drug, at-home treatment to slow memory and daily function loss in Alzheimer's disease.
What could go wrong
This is a pivotal study, but the device is still experimental. It may not show meaningful benefit over sham, and daily use for a year requires commitment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

673 people

The number who actually took part.

Started

Dec 2022

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and Women age 50-90 * Alzheimer's disease diagnosis with at least 6-month decline in cognitive function * Non-childbearing potential or using adequate birth control * Mini-Mental State Exam (MMSE) 15-28 * Available/consenting Study Partner * Able to identify a Legally Authorized Representative (LAR) * Stable chronic conditions at least 30 days * Formal education of 8 or more years * Adequate vision (Able to detect light) and hearing * Mobility sufficient for compliance with testing procedures (ambulatory or aided-ambulatory, i.e. cane or walker) * Amyloid or phosphorylated Tau positivity Exclusion Criteria: * Seizure disorder * Hospitalization in previous 30 days * Living in continuous care nursing home (assisted living permitted) * Inability to have an MRI or significant abnormality on MRI screening * Geriatric Depression Scale (GDS) \>6 * Suicidality (current or previous 6 months) * Serious neurological diseases affecting the Central Nervous System, including: 1. other primary degenerative dementias (Lewy-body dementia, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob disease, Down syndrome, mixed dementia, etc), 2. neurodegenerative conditions (Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, etc), 3. serious infection of the brain (meningitis/encephalitis), or 4. history of multiple concussions. * Metabolic or systemic diseases affecting the central nervous system (syphilis, B12 or folate deficiency, etc) * Schizophrenia or bipolar disorder * Heart disease, chronic liver, kidney, or respiratory disease, or uncontrolled diabetes or thyroid disease * Cancer history within previous 2 years (except resolved non-melanoma skin or stable prostate) * Nootropic drugs except stable acetylcholinesterase inhibitors * Drug or Alcohol abuse in previous 12 months * Previous exposure to Anti-amyloid-beta vaccines * Past Exposure to Immunomodulators or passive immunotherapies for AD (ie, monoclonal antibodies) * Exposure to BACE (β-Site amyloid precursor protein cleaving enzyme) inhibitors within the 6 months prior to consent * Involved in a previous Cognito study or gamma therapy study * Active treatment with Memantine (Namenda or Namzaric) within previous 30 days * Life expectancy \< 24 months Participants involved in the Fluid Biomarker substudy also must not have contraindications to lumbar puncture. For more information visit: https://www.hopestudyforad.com/

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Alzheimer disease 10 Alzheimer disease 11 Alzheimer disease 12 Alzheimer disease 13 Alzheimer disease 14 Alzheimer disease 16 Alzheimer disease 17 Alzheimer disease 18 Alzheimer disease 19 Alzheimer disease 2 Alzheimer disease 3 Alzheimer disease 4 Alzheimer disease 5 Alzheimer disease 6 Alzheimer disease 7 Alzheimer disease 8 Alzheimer disease 9 Alzheimer disease type 1 Alzheimer disease without neurofibrillary tangles Cognitive Dysfunction dementia early-onset autosomal dominant Alzheimer disease follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Alzheimer disease 1 Alzheimer disease 10 Alzheimer disease 11 Alzheimer disease 12 Alzheimer disease 13 Alzheimer disease 14 Alzheimer disease 15 Alzheimer disease 16 Alzheimer disease 17 Alzheimer disease 18 Alzheimer disease 19 Alzheimer disease 2 Alzheimer disease 3 Alzheimer disease 4 Alzheimer disease 5 Alzheimer disease 6 Alzheimer disease 7 Alzheimer disease 8 Alzheimer disease 9 Alzheimer disease, early onset Alzheimer disease, late onset Alzheimer's dementia late onset Cognitive decline Cognitive impairment Cognitive impairment, mild Dementia Dementia alzheimers Dementia moderate Dementia of Alzheimer type Dementia senile Dementia, mild MCI Mild cognitive impairment Mild dementia

Contacts and locations

Locations

  • ATP Clinical Research, Inc.

    Costa Mesa, California, 92626, United States

  • Advanced Research Center, Inc

    Anaheim, California, 92805, United States

  • Alphab Global Research

    Jupiter, Florida, 33458, United States

  • Alzheimer's Memory Center - AMC Research

    Matthews, North Carolina, 28105, United States

  • Aqualane Clinical Research

    Naples, Florida, 34105, United States

  • Arrow Clinical Trials

    Daytona Beach, Florida, 32117, United States

  • Axiom Clinical Research of Florida

    Tampa, Florida, 33609, United States

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Boston Center for Memory

    Newton, Massachusetts, 02459, United States

  • Boston Clinical Trials, Inc.

    Boston, Massachusetts, 02131, United States

  • Brain Matters Research

    Delray Beach, Florida, 33445, United States

  • Brain Matters Research

    Stuart, Florida, 34997, United States

  • CCT Research - Foothills Research Center

    Phoenix, Arizona, 85044, United States

  • CCT Research - Gilbert Neurology Partners

    Gilbert, Arizona, 85297, United States

  • CCT Research - Papillion Research Center

    Papillion, Nebraska, 68046, United States

  • Center for Cognitive Health - Portland

    Portland, Oregon, 97225, United States

  • Charter Research - Lady Lake

    Lady Lake, Florida, 32792, United States

  • Charter Research - Winter Park

    Winter Park, Florida, 32792, United States

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • Coastal Family Medicine - Orange Park

    Orange Park, Florida, 32073, United States

  • Coastal Neurology

    Port Royal, South Carolina, 29935, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Emerald Coast Neurology

    Pensacola, Florida, 32504, United States

  • Emory Alzheimer's Disease Research Center

    Atlanta, Georgia, 30329, United States

  • Great Lakes Clinical Trials- Flourish Research- Chicago

    Chicago, Illinois, 60640, United States

  • Great Lakes Clinical Trials- Flourish Research- Gurnee

    Gurnee, Illinois, 60031, United States

  • Hattiesburg Clinic

    Hattiesburg, Mississippi, 39401, United States

  • Insight Clinical Trials, LLC

    Beachwood, Ohio, 44122, United States

  • Integrative Clinical Trials, LLC

    Brooklyn, New York, 11229, United States

  • Intercoastal Medical Group - Sarasota

    Sarasota, Florida, 34239, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • Josephson Wallack Munshower Neurology, PC

    Indianapolis, Indiana, 46256, United States

  • K2 Medical Research - Orlando

    Orlando, Florida, 32806, United States

  • Las Vegas Medical Research

    Las Vegas, Nevada, 89113, United States

  • Mercury Clinical Research

    Sugarland, Texas, 77478, United States

  • Mid Hudson Medical Research

    New Windsor, New York, 12553, United States

  • Mile High Research Center

    Denver, Colorado, 80218, United States

  • Multi-Specialty Research Associates, Inc.

    Lake City, Florida, 23055, United States

  • Neuro-Behavioral Clinical Research

    Canton, Ohio, 44720, United States

  • NeuroStudies

    Decatur, Georgia, 30033, United States

  • Neurological Associates of Albany

    Albany, New York, 12208, United States

  • Neurology Center of North Orange County

    Fullerton, California, 92835, United States

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida, 33912, United States

  • North Texas Clinical Trials

    Fort Worth, Texas, 76104, United States

  • Northern Light Acadia Hospital

    Bangor, Maine, 04402, United States

  • Office of Donald S. Marks, M.D., P.C.

    Plymouth, Massachusetts, 02360, United States

  • Office of Elizabeth Zarate-Rowell, MD

    Seal Beach, California, 90740, United States

  • Premier Clinical Research Institute Inc.

    Miami, Florida, 30033, United States

  • Prisma Health Neurology

    Columbia, South Carolina, 29203, United States

  • Progressive Medical Research

    Port Orange, Florida, 32127, United States

  • QUEST Research Institute

    Farmington, Michigan, 48334, United States

  • Quantum Laboratories

    Pompano Beach, Florida, 33064, United States

  • ReCogniton Health

    Fairfax, Virginia, 22031, United States

  • Sisu BHR, LLC

    Springfield, Massachusetts, 01103, United States

  • South Lake Pain Institute

    Clermont, Florida, 34711, United States

  • Suncoast Neuroscience Associates

    St. Petersburg, Florida, 33713, United States

  • Syrentis Clinical Research

    Santa Ana, California, 92705, United States

  • TRS Health

    Stafford, Texas, 77477, United States

  • The Clinical Trial Center

    Jenkintown, Pennsylvania, 19046, United States

  • The Cognitive and Research Center of New Jersey

    Springfield, New Jersey, 07081, United States

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210, United States

  • UT Health San Antonio, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases

    San Antonio, Texas, 78229, United States

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

  • Velocity Clinical Research - Syracuse

    East Syracuse, New York, 13057, United States

  • Visionary Investigators Network- Aventura

    Aventura, Florida, 33180, United States

  • Visionary Investigators Network- Miami

    Miami, Florida, 33133, United States

  • Wasatch Clinical Research

    Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.